Thromb Haemost 2008; 99(06): 1085-1089
DOI: 10.1160/TH07-12-0755
Cardiovascular Biology and Cell Signalling
Schattauer GmbH

Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years

Loukianos S. Rallidis
1  Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
,
Marianna Politou
2  Laboratory of Haematology and Blood Transfusion Unit, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
,
Christoforos Komporozos
1  Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
,
Demosthenes B. Panagiotakos
3  Department of Nutrition Science – Dietetics, Harokopio University, Athens, Greece
,
Chrisoula I. Belessi
4  Department of Haematology, General Hospital of Hospital of Nikea, Piraeus, Greece
,
Anthi Travlou
2  Laboratory of Haematology and Blood Transfusion Unit, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
,
John Lekakis
1  Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
,
Dimitrios T. Kremastinos
1  Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece
› Author Affiliations
Further Information

Publication History

Received 27 December 2007

Accepted after major revision 31 March 2008

Publication Date:
27 November 2017 (online)

Summary

There are limited and controversial data regarding the impact of factor XIII (FXIII) Val34Leu polymorphism in the pathogenesis of premature myocardial infarction (MI). We examined whether FXIII Val34Leu polymorphism is associated with the development of early MI.We recruited 159 consecutive patients who had survived their first acute MI under the age of 36 years (mean age=32.1 ± 3.6 years, 138 were men). The control group consisted of 121 healthy individuals matched with cases for age and sex, without a family history of premature coronary heart disease (CHD). FXIII Val34Leu polymorphism was tested with polymerase chain reaction and reverse hybridization. There was a lower prevalence of carriers of the Leu34 allele in patients than in controls (30.2 vs. 47.1%, p=0.006). FXIII Val34Leu polymorphism was associated with lower risk for acute MI after adjusting for major cardiovascular risk factors (odds ratio [OR] = 0.51, 95% confidence interval [CI] 0.27–0.95, p=0.03). Subgroup analysis according to angiographic findings (“normal” coronary arteries [n=29] or significant CHD [n=130]) showed that only patients with MI and significant CHD had lower prevalence of carriers of the Leu34 allele compared to controls after adjusting for major cardiovascular risk factors (OR = 0.42, 95% CI 0.22–0.83, p=0.01). Our data indicate that FXIII Val34Leu polymorphism has a protective effect against the development of MI under the age of 36 years, particularly in the setting of significant CHD.